EP Patent

EP3078663A1 — Modified particles of palbociclib

Assigned to Sandoz AG · Expires 2016-10-12 · 10y expired

What this patent protects

The invention relates to crystalline free base of palbociclib having medium specific surface area, to flake- and/or plate-like primary particles of Palbociclib and to a modified salt break procedure for the preparation thereof. The invention is also directed to pharmaceutical com…

USPTO Abstract

The invention relates to crystalline free base of palbociclib having medium specific surface area, to flake- and/or plate-like primary particles of Palbociclib and to a modified salt break procedure for the preparation thereof. The invention is also directed to pharmaceutical compositions comprising an effective amount of palbociclib and a pH modifier and to the use of said pharmaceutical compositions as medicament, in particular for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3078663A1
Jurisdiction
EP
Classification
—
Expires
2016-10-12
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.